Profile data is unavailable for this security.
About the company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.
- Revenue in USD (TTM)1.44bn
- Net income in USD428.48m
- Incorporated2007
- Employees834.00
- LocationLantheus Holdings Inc331 Treble Cove RdNORTH BILLERICA 01862United StatesUSA
- Phone+1 (978) 671-8001
- Fax+1 (302) 636-5454
- Websitehttps://www.lantheus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procept Biorobotics Corp | 176.58m | -103.71m | 4.37bn | 626.00 | -- | 17.52 | -- | 24.75 | -2.06 | -2.06 | 3.50 | 4.85 | 0.546 | 1.85 | 3.83 | 282,068.70 | -32.07 | -- | -36.52 | -- | 54.73 | -- | -58.73 | -- | 6.49 | -- | 0.1696 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| DENTSPLY SIRONA Inc | 3.90bn | -185.00m | 5.33bn | 15.00k | -- | 1.74 | 32.50 | 1.37 | -0.8698 | -0.8698 | 18.65 | 15.12 | 0.5356 | 2.94 | 6.18 | 259,733.30 | -2.49 | -1.14 | -3.03 | -1.32 | 52.23 | 53.65 | -4.65 | -2.51 | 0.8692 | 3.65 | 0.4066 | -- | 1.10 | -0.1071 | 86.11 | -- | -4.54 | 9.86 |
| TransMedics Group Inc | 358.76m | 3.00m | 5.50bn | 584.00 | 3,999.03 | 28.95 | 316.38 | 15.34 | 0.0413 | 0.0413 | 10.61 | 5.70 | 0.4952 | 3.56 | 5.58 | 614,313.40 | 0.4141 | -16.08 | 0.4403 | -17.95 | 60.71 | 65.37 | 0.8362 | -40.47 | 8.48 | -- | 0.7278 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
| Merit Medical Systems Inc | 1.30bn | 117.43m | 5.80bn | 6.95k | 49.63 | 4.52 | 27.23 | 4.45 | 2.01 | 2.01 | 22.24 | 22.04 | 0.6183 | 2.30 | 7.36 | 187,231.10 | 5.58 | 2.45 | 6.13 | 2.77 | 46.54 | 44.50 | 9.02 | 3.91 | 4.64 | 17.52 | 0.3846 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Stevanato Group SpA | 1.21bn | 136.81m | 5.83bn | 5.64k | 37.50 | 3.56 | 25.73 | 4.80 | 0.5136 | 0.5136 | 4.54 | 5.42 | 0.543 | 2.66 | 2.80 | 215,440.70 | 6.12 | -- | 8.34 | -- | 30.06 | -- | 11.27 | -- | 1.13 | 44.77 | 0.1926 | -- | 10.34 | -- | 1.95 | -- | -- | -- |
| Inspire Medical Systems Inc | 705.71m | 6.01m | 6.35bn | 1.01k | 1,099.89 | 9.94 | 644.81 | 8.99 | 0.1935 | 0.1935 | 23.74 | 21.41 | 1.05 | 2.68 | 9.86 | 698,026.70 | 0.8927 | -11.27 | 0.99 | -12.60 | 84.83 | 84.47 | 0.8518 | -13.57 | 8.35 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
| Masimo Corp | 2.02bn | 79.40m | 6.49bn | 3.80k | 82.59 | 4.72 | 37.18 | 3.22 | 1.47 | 1.47 | 37.32 | 25.73 | 0.6831 | 1.94 | 5.77 | 530,763.20 | 2.69 | 8.65 | 3.32 | 10.31 | 49.28 | 57.30 | 3.94 | 12.03 | 1.15 | 3.30 | 0.3635 | 0.00 | 0.6042 | 19.00 | -43.21 | -15.96 | 31.06 | -- |
| Glaukos Corp | 341.73m | -158.61m | 7.02bn | 907.00 | -- | 10.53 | -- | 20.55 | -3.20 | -3.20 | 6.91 | 12.13 | 0.3642 | 1.67 | 7.55 | 376,764.10 | -16.91 | -8.73 | -18.20 | -9.35 | 76.53 | 74.77 | -46.41 | -28.69 | 4.67 | -56.93 | 0.16 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| Penumbra Inc | 1.13bn | 14.23m | 7.57bn | 4.20k | 571.01 | 6.52 | 174.64 | 6.68 | 0.3415 | 0.3415 | 28.94 | 29.90 | 0.7642 | 1.07 | 5.53 | 269,924.50 | 0.9595 | 2.32 | 1.07 | 2.61 | 65.45 | 63.90 | 1.26 | 3.17 | 3.77 | -- | 0.0209 | 0.00 | 24.95 | 18.93 | 4,643.16 | 68.60 | 9.64 | -- |
| Lantheus Holdings Inc | 1.44bn | 428.48m | 7.64bn | 834.00 | 18.02 | 7.44 | 15.64 | 5.31 | 6.11 | 6.11 | 20.48 | 14.79 | 0.8775 | 8.35 | 4.58 | 1,724,234.00 | 26.15 | 6.69 | 29.96 | 7.73 | 64.49 | 57.56 | 29.80 | 9.02 | 4.41 | -- | 0.3546 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Repligen Corp | 602.35m | -1.90m | 8.01bn | 1.78k | -- | 4.02 | 116.73 | 13.29 | -0.0416 | -0.0416 | 10.67 | 35.53 | 0.2226 | 1.46 | 4.95 | 337,831.80 | -0.0703 | 4.38 | -0.0782 | 5.03 | 47.70 | 55.43 | -0.3156 | 15.91 | 5.56 | -- | 0.2282 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Henry Schein, Inc. | 12.49bn | 352.00m | 9.02bn | 25.00k | 26.30 | 2.57 | 14.29 | 0.722 | 2.71 | 2.71 | 95.98 | 27.64 | 1.29 | 4.88 | 8.25 | 499,480.00 | 3.58 | 6.09 | 5.97 | 10.44 | 31.63 | 30.04 | 2.78 | 4.40 | 0.896 | 6.85 | 0.3333 | 0.00 | -2.44 | 5.55 | -22.68 | -0.1456 | 21.27 | -- |
| Bio Rad Laboratories Inc | 2.56bn | -1.33bn | 9.18bn | 8.03k | -- | 1.37 | -- | 3.58 | -47.03 | -47.03 | 89.18 | 240.39 | 0.2366 | 1.49 | 5.47 | 319,128.80 | -12.24 | 9.08 | -12.87 | 9.60 | 54.02 | 55.55 | -51.73 | 41.97 | 4.63 | 0.1653 | 0.1504 | 0.00 | -4.67 | 3.13 | 82.43 | -- | 3.83 | -- |
| Globus Medical Inc | 2.24bn | 40.68m | 9.57bn | 5.00k | 237.98 | 2.40 | 35.52 | 4.28 | 0.2968 | 0.2968 | 17.02 | 29.38 | 0.6207 | 1.63 | 5.25 | 447,306.00 | 1.13 | 6.90 | 1.30 | 7.45 | 59.65 | 71.73 | 1.82 | 14.05 | 1.45 | 455.56 | 0.098 | 0.00 | 53.34 | 17.08 | -35.39 | -4.72 | 5.57 | -- |
| Bruker Corp | 3.12bn | 352.10m | 10.23bn | 9.71k | 28.11 | 5.71 | 20.63 | 3.28 | 2.40 | 2.40 | 21.24 | 11.82 | 0.6393 | 1.47 | 5.90 | 321,386.60 | 7.21 | 8.38 | 9.59 | 11.40 | 50.08 | 49.85 | 11.28 | 11.39 | 0.7244 | 43.06 | 0.5419 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
Data as of Sep 20 2024. Currency figures normalised to Lantheus Holdings Inc's reporting currency: US Dollar USD
43.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.44m | 10.74% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.17m | 10.34% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 3.80m | 5.48% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.49m | 3.59% |
| Westfield Capital Management Co. LPas of 31 Mar 2024 | 1.96m | 2.83% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.65m | 2.38% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 1.48m | 2.14% |
| Reinhart Partners, Inc.as of 30 Jun 2024 | 1.47m | 2.12% |
| Macquarie Investment Management Business Trustas of 30 Jun 2024 | 1.38m | 1.99% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.31m | 1.89% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
